The EINSTEIN-PE trial showed that rivaroxaban has equal efficacy and a lower rate of bleeding than coumarins in the treatment of acute pulmonary embolism. We anticipate regulatory and consumer acceptance for rivaroxaban, representing the first new anticoagulant treatment for venous thromboembolism since the introduction of warfarin compounds 50 years ago.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Büller, H. R. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366, 1287–1297 (2012).
Lee, A. & Crowther, M. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J. Thromb. Thrombolysis 31, 249–258 (2011).
Ageno, W. et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2 Suppl.), e44S–e88S (2012).
Samama, M. M. et al. Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb. Hemost. 103, 815–825 (2010).
Samama, M. M. et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb. Hemost. 107, 379–387 (2012).
Deitelzweig, S. et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trials. J. Med. Econ. http://dx.doi.org/10.3111/13696998.2012.680555.
Holbrook, A. et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2 Suppl.), e152S–e184S (2012).
Ninjkeuter, M., Hovens, M. M., Davidson, B. L. & Huisman, M. V. Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review. Chest 129, 192–197 (2006).
Kline, J. A. & Miller, D. W. Risk stratification for acute pulmonary embolism. J. Natl Compr. Canc. Netw. 9, 800–810 (2011).
Jaff, M. R. et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 123, 1788–1830 (2011).
Acknowledgements
The work was supported by Awards Number 1R01HL085565-01 and 1K12 HL109068-01 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J. A. Kline has received grant support from the Agency for Healthcare Research and Quality and Genentech. He is a stock holder in CP Diagnostics LLC. D. M. Yealy has received grant support from the National Institutes of Health.
Rights and permissions
About this article
Cite this article
Kline, J., Yealy, D. EINSTEIN transforms anticoagulant therapy in acute PE. Nat Rev Cardiol 9, 378–380 (2012). https://doi.org/10.1038/nrcardio.2012.65
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2012.65
